CEL-SCI Enrolls 22 Patients During October In Its Phase III Immunotherapy Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of October the Company enrolled 22 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). This brings the total number patients enrolled in the world's largest Phase III trial for head and neck cancer to almost 300. A total of 880 patients are expected to be enrolled, through 100 clinical centers in over 20 countries. “To date, our study has been cleared in 17 countries on three continents and we expect to add more clinics across these regions where an increasing number of patients will be enrolled in the coming months and quarters. With 22 patients enrolled in October, we have now set a new record for monthly recruitment following a slower summer recruitment period. We expect this upward trend to continue,” stated CEL-SCI Chief Executive Officer Geert Kersten. The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only. CEL-SCI's Multikine investigational immunotherapy is intended to create an anti-tumor immune response to reduce local/regional tumor recurrence and thereby increase the survival rate of these patients. About Multikine Phase III Study The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only.